RxDoctor Payments Data

Muhammad Chaudhry, MD

Internal Medicine · Mesa, AZNPI 1609001262

Payments from drug & device makers

$5,318in general payments, 2019–2025

Across 44 payments — averaging $120.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Edwards Lifesciences$554
  • Abiomed$478
  • AstraZeneca$265
  • Boehringer Ingelheim$127
  • Terumo Medical Corporation$97
  • plus $370 from 11 others

What the payments were for

  • Grants$1,10521%
  • Travel & lodging$2,29243%
  • Food & beverage$1,92136%

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,318 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$121,321
Medicare patients
245
Services billed
1,214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban430$501,034
XareltoRivaroxaban118$129,802
EntrestoSacubitril/Valsartan63$68,844
JardianceEmpagliflozin52$63,493
Repatha SureclickEvolocumab21$27,644
FarxigaDapagliflozin Propanediol27$21,943
BrilintaTicagrelor17$18,297
Metoprolol Succinate685$8,772
ClopidogrelClopidogrel Bisulfate468$5,657
Atorvastatin Calcium522$5,190
Losartan Potassium353$4,133
Ranolazine ErRanolazine40$3,476
Ezetimibe73$2,366
Amlodipine Besylate332$2,261
Rosuvastatin Calcium140$2,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$35$501,034430 claims
NovartisEntresto$19$68,84463 claims
Boehringer IngelheimJardiance$127$63,49352 claims
AstraZenecaFarxiga, Brilinta$265$40,24044 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →